Alliance Enhances Anti-Infective and Respiratory Offerings

LGC, an international leader in the laboratory services, measurement standards, reference materials, genomics and proficiency testing marketplaces, and TranScrip Partners, a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and lifecycle management, have announced a strategic alliance that allows both parties to combine and enhance their offerings to clients, particularly in the areas of anti-infectives and respiratory disease.

TranScrip Partners supplies a wide range of services, including drug development and operations, regulatory affairs, microbiology, medical writing, translational medicine, drug safety and pharmacovigilance. LGC is a provider of high-integrity analytical laboratory services to support drug discovery, development and manufacture. With last year’s acquisition of Quotient Bio Analytical Sciences, LGC also has a leading bioanalytical facility with expertise spanning small molecules, biopharmaceuticals, biomarkers, microbiology and molecular services,

Dr. David Griffiths, Director, Pharmaceutical Services at LGC, said: “We’re really excited by this development. LGC’s high quality laboratory services and TranScrip’s expertise in drug development strategy, medical writing and regulatory affairs complement each other beautifully. Whilst both companies support all therapeutic areas, we have a combined strength in anti-infectives.”

Felicity Gabbay, Managing Partner at TranScrip Partners, added: “TranScrip have an enviable reputation for drug development, registration and post licensing support in anti-infectives, particularly antibiotics, and our alliance with LGC will allow us to extend this capability into vital laboratory support for these programmes. We are therefore delighted about the two companies coming together.”

On 3 October LGC is hosting an Autumn Seminar on Respiratory Product Development at its site in Fordham, Cambridgeshire, UK. Among the speakers will be TranScrip Partners’ Professor Tim Higenbottam, presenting on ‘Regulatory strategies for respiratory product development: opportunities and pitfalls’. To see the full programme and to register, click here.

LGC, +44 20 8943 8491, julian.quigley@lgcgroup.com, www.lgcgroup.com.